Brief: US FDA Grants Priority Review to Zepzelca + Tecentriq for 1st-Line ES-SCLC Maintenance Therapy
10/06/2025 12:10
June 10 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: ZEPZELCA® (LURBINECTEDIN) AND ATEZOLIZUMAB (TECENTRIQ®) COMBINATION GRANTED U.S. FDA PRIORITY REVIEW FOR FIRST-LINE MAINTENANCE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER JAZZ PHARMACEUTICALS PLC - PDUFA ACTION DATE SET FOR OCTOBER 7, 2025 Source text: ID:nPn8x33pda Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032